Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Gene Amplification”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Testing effectiveness (Phase 2)Study completedNCT03783936
What this trial is testing

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Who this might be right for
Gastric AdenocarcinomaEsophageal AdenocarcinomaMetastasis+1 more
Ashwin Somasundaram 18
Not applicableUnknownNCT03979911
What this trial is testing

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsHER-2 Gene Amplification
University Hospital, Brest 63
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics 30
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Not applicableStudy completedNCT01066507
What this trial is testing

Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections

Who this might be right for
Breast Cancer
Applied Spectral Imaging Ltd. 126
Not applicableLooking for participantsNCT04324125
What this trial is testing

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110
What this trial is testing

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 38
Testing effectiveness (Phase 2)UnknownNCT05274191
What this trial is testing

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Zhongshan Hospital Xiamen University 60
Testing effectiveness (Phase 2)UnknownNCT03418558
What this trial is testing

Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

Who this might be right for
Metastatic Colorectal Cancer
Fondazione del Piemonte per l'Oncologia 13
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT02004769
What this trial is testing

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification
Sun Yat-sen University 67
Testing effectiveness (Phase 2)Study completedNCT00006089
What this trial is testing

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaERBB2 Gene AmplificationRecurrent Uterine Corpus Carcinoma+2 more
National Cancer Institute (NCI) 34
Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT02314481
What this trial is testing

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Who this might be right for
Non-small Cell Lung Cancer
University College, London 50
Early research (Phase 1)Temporarily pausedNCT04650451
What this trial is testing

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Who this might be right for
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast Cancer+2 more
Bellicum Pharmaceuticals 220
Testing effectiveness (Phase 2)UnknownNCT04215159
What this trial is testing

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Who this might be right for
HER-2 Protein OverexpressionHER-2 Gene Amplification
Jin-Hee Ahn 42
Early research (Phase 1)Active Not RecruitingNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 93
Testing effectiveness (Phase 2)Active Not RecruitingNCT04818333
What this trial is testing

SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 157
Load More Results